Guggenheim lowered the firm’s price target on Janux Therapeutics (JANX) to $68 from $72 and keeps a Buy rating on the shares after the firm updated its model for the latest quarter.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics: Rebuilding Confidence After JANX007 Setback with 2026 Clinical Catalysts and Validated PSMA x CD3 Platform
- Janux Therapeutics reports Q4 EPS (51c), consensus (64c)
- Janux Therapeutics doses first patient in JANX011 trial
- Janux Therapeutics CMO Zachariah McIver to depart, William Go to succeed
- Janux Therapeutics Inks Global Oncology Collaboration With BMS